

INDGN/SE/2025-26/56

September 19, 2025

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN
---	---

Dear Sir / Madam,

Sub: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed the copy of Press Release dated September 19, 2025, titled "Datavant and Indegene Partner to Power More Efficient Clinical Trial Recruitment".

Kindly take the same on records.

Thanking you,

Yours Sincerely,

For Indegene Limited

Srishti Ramesh Kaushik
Company Secretary and Compliance Officer

Encl: As above



Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy
Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru-
560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
www.indegene.com

CIN: L73100KA1998PLC102040



Press release

Datavant and Indegene Partner to Power More Efficient Clinical Trial Recruitment

Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials

New York / Princeton / Bengaluru, September 19, 2025: Datavant, the data collaboration platform trusted for healthcare, announced a strategic partnership with Indegene, a leading digital-first, life sciences commercialization company, today to enhance patient recruitment for clinical trials, with a focus on rare disease and other complex studies. By embedding Datavant's bespoke data enrichment capabilities into Indegene's NEXT Patient Recruitment platform, the two companies are enabling faster trial enrollment, fewer screen failures, and more efficient recruitment processes for biopharmaceutical organizations.

Patient recruitment is one of the biggest hurdles in clinical development, particularly in rare diseases where eligible populations are small and dispersed. Datavant operates the nation's largest health data retrieval network, spanning more than 80,000 hospitals and clinics and processing over 100 million patient records annually. Combined with Indegene's suite of digitally powered solutions for clinical trial recruitment, the partnership streamlines the identification of suitable participants for studies based on specific health data criteria.

The result is more eligible participants have an opportunity to connect to the trials designed for their specific health conditions, including patients with rare and complex diseases. The partnership enables biopharma companies to reduce site-level screen failures, accelerate enrollment timelines, improve the screen-to-randomization ratios, and drive more informed decision-making.

"Rare diseases have long been defined by the impossibility of finding enough patients fast enough to bring new therapies to market," said Arnaub Chatterjee, President and GM of Life Sciences of Datavant. "Together with Indegene, we are demonstrating how data enrichment solves that challenge today – and lays the foundation for a new model of clinical research in which sponsors can accelerate recruitment across even the most complex and hard-to-reach populations."

"We are doubling down on enhancing our capabilities to deliver digital-first recruitment solutions for clients to transform clinical trial execution. Our partnership with Datavant is a key step in this journey," said Ram Yeleswarapu, SVP, Enterprise Clinical Solutions at Indegene. "By integrating secure, real-time access to consented patient medical records into our screening process, we are minimizing one of the greatest challenges in clinical trials – screen failures at sites due to incomplete and ineffective pre-screening. This collaboration reinforces our positioning as the industry's premier digital-first recruitment partner, empowering sponsors and sites with data-driven approaches that deliver measurable outcomes."



About Indegene

Indegene Limited (BSE: 544172, NSE: INDGN) is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient and modern way. Indegene brings together healthcare domain expertise, fit-for-purpose technology and an agile operating model to provide a diverse range of solutions. These aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. It's what drives Indegene's team and their purpose to enable healthcare organizations to be future-ready. To learn more, please visit www.indegene.com

About Datavant

Datavant is the data collaboration platform trusted for healthcare. With a mission to make the world's health data secure, accessible, and actionable, Datavant works with payers, providers, life sciences, legal and insurance clients globally to accelerate insights. Datavant enables more than 60 million healthcare records to move between thousands of organizations across the healthcare ecosystem, more than 80,000 hospitals and clinics, 75% of the 100 largest health systems, and 350+ real-world data partners. Datavant has office locations in Boston, New York and San Diego, with international offices in Barcelona and Galway. To learn more about Datavant, visit datavant.com and follow us on [LinkedIn](#).

For media inquiries, please contact:

Indegene | Yadunandan K V | yadunandan.kv@indegene.com

Datavant | Lynn Shepherd | lynn.shepherd@datavant.com